Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer-Reference-Cited by-全球学者库

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer

Published:2021-05 Issue: Volume:Volume 14 Page:1797-1809
ISSN:1178-7074
Container-title:International Journal of General Medicine
language:en
Short-container-title:IJGM

Author:

Li Yi,Liu Cheng,Wang Bibo,Hu Xichun,Gong Chengcheng,Zhao Yannan,Xie Yizhao,Zhang Yingjian,Song Shaoli,Yang Zhongyi,Wang Biyun

Publisher

Informa UK Limited

Subject

General Medicine

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

3. Howlader NN, Noone AM, Krapcho M et al. SEER cancer statistics review, 1975–2013 (based on November 2015 SEER data submission, posted to the SEER web site, 2016). 2016. Available from: http://seer.cancer.gov/csr/1975_2013/. Accessed May 1, 2021.

4. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016

5. Molecular portraits of human breast tumours

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data;Cancers;2023-11-20

2. 18F-FES and 18F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment;Annals of Nuclear Medicine;2023-10-03

3. Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer;Cancer Imaging;2023-09-19

4. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant;Clinical Cancer Research;2023-02-03

5. Molecular imaging as biomarker for treatment response and outcome in breast cancer;Therapeutic Advances in Medical Oncology;2023-01